MCID: LMB002
MIFTS: 58

Lambert-Eaton Myasthenic Syndrome

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Lambert-Eaton Myasthenic Syndrome

MalaCards integrated aliases for Lambert-Eaton Myasthenic Syndrome:

Name: Lambert-Eaton Myasthenic Syndrome 12 50 55 36 51 41 14 69
Lems 12 49
Myasthenic-Myopathic Syndrome of Lambert-Eaton 49
Myasthenic Syndrome of Lambert-Eaton 49
Lambert Eaton Myasthenic Syndrome 49
Eaton-Lambert Syndrome 12
Lambert-Eaton Syndrome 12
Eaton Lambert Syndrome 49
Lambert Eaton Syndrome 49

Characteristics:

Orphanet epidemiological data:

55
lambert-eaton myasthenic syndrome
Inheritance: Not applicable; Prevalence: <1/1000000 (Netherlands),1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:0050214
ICD10 32 G70.80 G73.1
ICD9CM 34 358.3
MeSH 41 D015624
NCIt 46 C3155
SNOMED-CT 64 230688006 56989000
Orphanet 55 ORPHA43393
MESH via Orphanet 42 D015624
UMLS via Orphanet 70 C0022972
ICD10 via Orphanet 33 G73.1
KEGG 36 H01596
UMLS 69 C0022972

Summaries for Lambert-Eaton Myasthenic Syndrome

NINDS : 50 Lambert-Eaton myasthenic syndrome (LEMS) is a disorder of the neuromuscular junction-the site where nerve cells meet muscle cells and help activate the muscles. It is caused by a disruption of electrical impulses between these nerve and muscle cells. LEMS is an autoimmune condition; in such disorders the immune system, which normally protects the body from foreign organisms, mistakenly attacks the body's own tissues. The disruption of electrical impulses is associated with antibodies produced as a consequence of this autoimmunity. Symptoms include muscle weakness, a tingling sensation in the affected areas, fatigue, and dry mouth. LEMS is closely associated with cancer, in particular small cell lung cancer. More than half the individuals diagnosed with LEMS also develop small cell lung cancer. LEMS may appear up to 3 years before cancer is diagnosed.

MalaCards based summary : Lambert-Eaton Myasthenic Syndrome, also known as lems, is related to congenital myasthenic syndrome and paraneoplastic cerebellar degeneration, and has symptoms including xerostomia, reduced tendon reflexes and dysautonomia. An important gene associated with Lambert-Eaton Myasthenic Syndrome is CACNB2 (Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2), and among its related pathways/superpathways are ERK Signaling and Transmission across Chemical Synapses. The drugs 4-Aminopyridine and 3,4-diaminopyridine have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and prostate, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A neuromuscular junction disease that is characterized by an abnormality of acetylcholine (ACh) release at the neuromuscular junction which results from an autoimmune attack against voltage-gated calcium channels (VGCC) on the presynaptic motor nerve terminal.

NIH Rare Diseases : 49 Lambert Eaton myasthenic syndrome (LEMS) is a disorder of the neuromuscular junction. The neuromuscular junction is the site where nerve cells meet muscle cells and help activate the muscles. This syndrome occurs when antibodies interfere with electrical impulses between the nerve and muscle cells. It may be associated with other autoimmune diseases, or more commonly coincide with or precede a diagnosis of cancer such as small cell lung cancer. Symptoms may include muscle weakness, a tingling sensation in the affected areas, fatigue, and dry mouth. Treatment of an underlying disorder or cancer is the first priority of treatment. Last updated: 12/22/2016

Wikipedia : 72 Lambert–Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder characterized by muscle weakness... more...

Related Diseases for Lambert-Eaton Myasthenic Syndrome

Diseases related to Lambert-Eaton Myasthenic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 congenital myasthenic syndrome 31.0 CACNA1A MUSK SYT2
2 paraneoplastic cerebellar degeneration 30.3 CACNA1A ENO2
3 paraneoplastic syndromes 11.8
4 myasthenic syndrome, congenital, 7, presynaptic 11.4
5 paraneoplastic neurologic disorders 11.4
6 tularemia 10.9
7 lambert syndrome 10.9
8 myasthenia gravis 10.9
9 myasthenia gravis congenital 10.9
10 lung cancer 10.9
11 small cell cancer of the lung 10.8
12 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
13 cerebellar degeneration 10.7
14 small cell carcinoma 10.6
15 respiratory failure 10.6
16 adenocarcinoma 10.5
17 neuronitis 10.5
18 subacute cerebellar degeneration 10.5
19 lupus erythematosus 10.4
20 systemic lupus erythematosus 10.4
21 ataxia and polyneuropathy, adult-onset 10.4
22 aceruloplasminemia 10.4
23 ataxia-oculomotor apraxia 3 10.4
24 polyglucosan body myopathy 1 with or without immunodeficiency 10.4
25 arthritis 10.4
26 dermatomyositis 10.4
27 merkel cell carcinoma 10.4
28 mediastinitis 10.4
29 neuropathy 10.4
30 autonomic dysfunction 10.4
31 rheumatoid arthritis 10.3
32 neuroblastoma 10.3
33 leukemia 10.3
34 prostatitis 10.3
35 transitional cell carcinoma 10.3
36 encephalitis 10.3
37 limbic encephalitis 10.3
38 thymic hyperplasia 10.3
39 autoimmune disease 10.1
40 blood group, i system 10.1
41 leiomyoma, uterine 10.1
42 strabismus 10.1
43 thymoma, familial 10.1
44 suppression of tumorigenicity 12 10.1
45 wilms tumor 5 10.1
46 panbronchiolitis, diffuse 10.1
47 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 10.1
48 psoriatic arthritis 10.1
49 autoimmune disease 1 10.1
50 lung cancer susceptibility 3 10.1

Graphical network of the top 20 diseases related to Lambert-Eaton Myasthenic Syndrome:



Diseases related to Lambert-Eaton Myasthenic Syndrome

Symptoms & Phenotypes for Lambert-Eaton Myasthenic Syndrome

Human phenotypes related to Lambert-Eaton Myasthenic Syndrome:

55 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 xerostomia 55 31 hallmark (90%) Very frequent (99-80%) HP:0000217
2 reduced tendon reflexes 55 31 hallmark (90%) Very frequent (99-80%) HP:0001315
3 dysautonomia 55 31 hallmark (90%) Very frequent (99-80%) HP:0002459
4 progressive proximal muscle weakness 55 31 hallmark (90%) Very frequent (99-80%) HP:0009073
5 calcium channel antibody positivity 55 31 hallmark (90%) Very frequent (99-80%) HP:0030209
6 impotence 55 31 frequent (33%) Frequent (79-30%) HP:0000802
7 constipation 55 31 frequent (33%) Frequent (79-30%) HP:0002019
8 bulbar signs 55 31 frequent (33%) Frequent (79-30%) HP:0002483
9 small cell lung carcinoma 55 31 frequent (33%) Frequent (79-30%) HP:0030357
10 hypohidrosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000966
11 keratoconjunctivitis sicca 55 31 occasional (7.5%) Occasional (29-5%) HP:0001097
12 orthostatic hypotension due to autonomic dysfunction 55 31 occasional (7.5%) Occasional (29-5%) HP:0004926
13 emg: decremental response of compound muscle action potential to repetitive nerve stimulation 55 Very frequent (99-80%)
14 emg: repetitive nerve stimulation abnormality 55 Very frequent (99-80%)
15 abnormality of the orbital region 55 Frequent (79-30%)
16 emg 31 hallmark (90%) HP:0003403

GenomeRNAi Phenotypes related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.4 MUSK
2 Decreased viability GR00173-A 9.4 MUSK
3 Decreased viability GR00221-A-1 9.4 SOX2 MUSK
4 Decreased viability GR00221-A-2 9.4 TTN
5 Decreased viability GR00221-A-4 9.4 SOX2 SYT2 TTN MUSK
6 Decreased viability GR00342-S-1 9.4 TTN
7 Decreased viability GR00342-S-3 9.4 TTN
8 Decreased viability GR00381-A-1 9.4 SYT2

MGI Mouse Phenotypes related to Lambert-Eaton Myasthenic Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 CACNA1A SOX3 CACNA1B SYT2 TTN ENO2
2 growth/size/body region MP:0005378 9.91 SOX3 CACNA1B SYT2 CACNB2 TTN ENO2
3 homeostasis/metabolism MP:0005376 9.76 SOX2 CACNA1A SOX3 CACNA1B CACNB2 TTN
4 craniofacial MP:0005382 9.72 SOX3 CACNB2 TTN ENO2 SOX2
5 mortality/aging MP:0010768 9.61 SOX3 CACNA1B SYT2 CACNB2 TTN ERC1
6 nervous system MP:0003631 9.23 CACNA1A SOX3 CACNA1B CACNB2 SYT2 ENO2

Drugs & Therapeutics for Lambert-Eaton Myasthenic Syndrome

Drugs for Lambert-Eaton Myasthenic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 3,Phase 2 504-24-5 1727
2 3,4-diaminopyridine Phase 3,Phase 2
3 Potassium Channel Blockers Phase 3,Phase 2
4
Ephedrine Approved Phase 1, Phase 2 299-42-3 9294
5
Pseudoephedrine Approved Phase 1, Phase 2 90-82-4 7028
6 Adrenergic Agents Phase 1, Phase 2
7 Anti-Asthmatic Agents Phase 1, Phase 2
8 Autonomic Agents Phase 1, Phase 2
9 Bronchodilator Agents Phase 1, Phase 2
10 Central Nervous System Stimulants Phase 1, Phase 2
11 Nasal Decongestants Phase 1, Phase 2
12 Neurotransmitter Agents Phase 1, Phase 2
13 Peripheral Nervous System Agents Phase 1, Phase 2
14 Respiratory System Agents Phase 1, Phase 2
15 Vasoconstrictor Agents Phase 1, Phase 2
16 Adrenergic Agonists Phase 1
17 Adrenergic beta-2 Receptor Agonists Phase 1
18 Adrenergic beta-Agonists Phase 1
19 Albuterol Phase 1
20 Tocolytic Agents Phase 1
21
nivolumab Approved 946414-94-4

Interventional clinical trials:

(show all 22)

# Name Status NCT ID Phase Drugs
1 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3 Amifampridine Phosphate;Placebo
2 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Completed NCT02970162 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
3 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes Recruiting NCT02562066 Phase 3 amifampridine phosphate;Placebo
4 Ephedrine for the Treatment of Congenital Myasthenia Unknown status NCT00541216 Phase 1, Phase 2 Ephedrine
5 Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome Completed NCT01511978 Phase 2 Continuous 3,4-DAP;Taper 3,4-DAP to Placebo
6 Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes Completed NCT01203592 Phase 1 Albuterol
7 Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Completed NCT00004832 3,4-diaminopyridine
8 Pregnancy Outcomes in Congenital Myasthenie Syndrome Completed NCT01474980
9 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) Recruiting NCT00872950 3,4-DIAMINOPYRIDINE;3,4-Diaminopyridine
10 Congenital Muscle Disease Study of Patient and Family Reported Medical Information Recruiting NCT01403402
11 National Registry for Egyptian Pediatric Neuromuscular Diseases Recruiting NCT02124616
12 Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice Recruiting NCT02847728
13 Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine Available NCT00994916 3,4 diaminopyridine
14 Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome Available NCT03062631 3,4-Diaminopyridine
15 Treatment of Lambert-Eaton Syndrome With 3,4 DAP Available NCT00704925 3, 4 DAP
16 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM) Available NCT02012933 3,4-diaminopyridine
17 Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome Available NCT01825395 3, 4-Diaminopyridine
18 Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients Available NCT02189720 Amifampridine Phosphate
19 Treatment Use of 3,4-Diaminopyridine Available NCT01765140 3,4-diaminopyridine;3,4-diaminopyridine
20 Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) Enrolling by invitation NCT02090725 3-4 Diaminopyridine
21 Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome No longer available NCT01373333 3,4 DAP
22 Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP No longer available NCT01378546 3,4-diaminopyridine

Search NIH Clinical Center for Lambert-Eaton Myasthenic Syndrome

Cochrane evidence based reviews: lambert-eaton myasthenic syndrome

Genetic Tests for Lambert-Eaton Myasthenic Syndrome

Anatomical Context for Lambert-Eaton Myasthenic Syndrome

MalaCards organs/tissues related to Lambert-Eaton Myasthenic Syndrome:

38
Lung, Testes, Prostate, T Cells, B Cells, Pituitary, Breast

Publications for Lambert-Eaton Myasthenic Syndrome

Articles related to Lambert-Eaton Myasthenic Syndrome:

(show top 50) (show all 389)
# Title Authors Year
1
Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads. ( 29125190 )
2018
2
Lambert-Eaton myasthenic syndrome and cerebellar ataxia: Is response to immunotherapy a clue to pathogenesis? ( 29365352 )
2018
3
3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome: Concerns regarding presentation of previous studies. ( 29406572 )
2018
4
3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome. ( 29402568 )
2018
5
The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome. ( 29191521 )
2018
6
Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome Associated with Neuroendocrine Carcinoma of the Oropharynx. ( 29093415 )
2018
7
Ophthalmoplegia associated with lung adenocarcinoma in a patient with the Lambert-Eaton myasthenic syndrome: A case report. ( 28562525 )
2017
8
Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. ( 28251917 )
2017
9
Adenocarcinoma of Lung Presenting as Lambert-Eaton Myasthenic Syndrome. ( 28785598 )
2017
10
Distinguishing Features of the Repetitive Nerve Stimulation Test Between Lambert-Eaton Myasthenic Syndrome and Myasthenia Gravis, 50-Year Reappraisal. ( 29189551 )
2017
11
Paraneoplastic Lambert-Eaton Myasthenic Syndrome With Limbic Encephalitis: Clinical Correlation With the Coexistence of Anti-VGCC and Anti-GABAB Receptor Antibodies. ( 29189554 )
2017
12
Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. ( 28608304 )
2017
13
Pediatric Lambert-Eaton Myasthenic Syndrome. ( 28178777 )
2017
14
Lambert-Eaton myasthenic syndrome with anti-acetylcholine receptor antibody and anterior mediastinal tumor. ( 29264043 )
2017
15
Lambert-Eaton Myasthenic Syndrome with A Twenty-Three-Year Delay in Diagnosis. ( 28680320 )
2017
16
Relapse of both small cell lung cancer and Lambert-Eaton myasthenic syndrome after a 13-year disease-free survival period. ( 27370896 )
2016
17
Lambert-Eaton myasthenic syndrome (LEMS): Epidemiology and therapeutic response in the national Veterans Affairs (VA) population. ( 27997683 )
2016
18
Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine. ( 27506750 )
2016
19
Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome. ( 27922503 )
2016
20
Tubular aggregates in autoimmune Lambert-Eaton myasthenic syndrome. ( 27816328 )
2016
21
Successful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report. ( 26998103 )
2016
22
Modelling the response to low-frequency repetitive nerve stimulation of myasthenia gravis and Lambert-Eaton myasthenic syndrome. ( 27016366 )
2016
23
Lambert-Eaton myasthenic syndrome in a patient with small-cell lung cancer: A case report. ( 26622673 )
2015
24
Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report. ( 26170921 )
2015
25
Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports. ( 25885033 )
2015
26
Lambert-Eaton myasthenic syndrome and Merkel cell carcinoma. ( 26452332 )
2015
27
Lambert-Eaton myasthenic syndrome in patients with small cell lung cancer: Report of five cases. ( 26323934 )
2015
28
Lambert-Eaton myasthenic syndrome associated with thymic neuroendocrine carcinoma. ( 25702627 )
2015
29
Efficacy of intravenous immunoglobulin for treatment of Lambert-Eaton myasthenic syndrome without anti-presynaptic P/Q-type voltage-gated calcium channel antibodies: a case report. ( 25444432 )
2015
30
Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism. ( 26502758 )
2015
31
Lambert-Eaton myasthenic syndrome associated to Merkel cell carcinoma: report of a case. ( 25698125 )
2015
32
Lambert-Eaton Myasthenic Syndrome: Ocular Signs and Symptoms. ( 25993122 )
2015
33
Lambert-Eaton myasthenic syndrome and prostatic adenocarcinoma. ( 26143177 )
2015
34
Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature. ( 26109387 )
2015
35
Post-exercise exhaustion in Lambert-Eaton myasthenic syndrome. ( 24128793 )
2014
36
The exhaustibility of Lambert-Eaton myasthenic syndrome. ( 24125855 )
2014
37
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. ( 24481713 )
2014
38
Lambert-Eaton myasthenic syndrome during anesthesia: a report of 37 patients. ( 25468580 )
2014
39
Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome. ( 25195700 )
2014
40
Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome. ( 24464710 )
2014
41
Lambert-Eaton myasthenic syndrome in a 13-year-old girl with Xp11.22-p11.23 duplication. ( 24461257 )
2014
42
Limbic encephalitis and Lambert Eaton myasthenic syndrome - An immunological profile of a new syndrome. ( 24269050 )
2014
43
Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist. ( 25015919 )
2014
44
Lung squamous carcinoma with two paraneoplastic syndromes -Dermatomyositis and Lambert-Eaton myasthenic syndrome. ( 25335449 )
2014
45
Myasthenia gravis and lambert-eaton myasthenic syndrome. ( 25299290 )
2014
46
Conjoint occurrence of GABAB receptor antibodies in Lambert-Eaton myasthenic syndrome with antibodies to the voltage gated calcium channel. ( 24929678 )
2014
47
Surgery results in complete cure of Lambert-Eaton myasthenic syndrome in a patient with metastatic Merkel cell carcinoma. ( 24704152 )
2014
48
Myasthenis Gravis or Lambert-Eaton Myasthenic Syndrome? ( 25133625 )
2014
49
Lambert-Eaton myasthenic syndrome - Diagnosis, pathogenesis and therapy. ( 25065299 )
2014
50
Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy. ( 25192047 )
2014

Variations for Lambert-Eaton Myasthenic Syndrome

Expression for Lambert-Eaton Myasthenic Syndrome

Search GEO for disease gene expression data for Lambert-Eaton Myasthenic Syndrome.

Pathways for Lambert-Eaton Myasthenic Syndrome

Pathways related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 CACNA1A CACNA1B CACNB2 MUSK SOX2 SOX3
2
Show member pathways
12.67 CACNA1A CACNA1B CACNB2 SYT2
3
Show member pathways
12.47 CACNA1A CACNA1B CACNB2
4
Show member pathways
12.18 CACNA1A CACNA1B CACNB2
5
Show member pathways
12.06 CACNA1A CACNA1B CACNB2
6 11.96 CACNA1A CACNA1B CACNB2
7
Show member pathways
11.9 CACNA1A CACNA1B CACNB2
8 11.65 CACNA1A CACNA1B CACNB2
9
Show member pathways
11.55 CACNA1A CACNA1B CACNB2
10 11.13 SOX2 SOX3
11 11.09 CACNA1A CACNA1B CACNB2
12 11.06 CACNA1A CACNA1B
13 10.9 CACNA1A CACNA1B CACNB2
14 10.73 CACNA1A CACNA1B
15 10.49 CACNA1A CACNA1B CACNB2
16 10.23 CACNA1A CACNA1B

GO Terms for Lambert-Eaton Myasthenic Syndrome

Cellular components related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.35 CACNA1A CACNA1B ERC1 MUSK SYT2
2 voltage-gated calcium channel complex GO:0005891 8.8 CACNA1A CACNA1B CACNB2

Biological processes related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.67 CACNA1A CACNA1B CACNB2
2 negative regulation of neuron differentiation GO:0045665 9.52 SOX2 SOX3
3 neurotransmitter secretion GO:0007269 9.51 CACNA1B SYT2
4 regulation of ion transmembrane transport GO:0034765 9.5 CACNA1A CACNA1B CACNB2
5 calcium ion-regulated exocytosis of neurotransmitter GO:0048791 9.48 CACNA1A SYT2
6 regulation of calcium ion-dependent exocytosis GO:0017158 9.46 CACNA1A SYT2
7 neuromuscular junction development GO:0007528 9.43 CACNB2 MUSK
8 pituitary gland development GO:0021983 9.4 SOX2 SOX3
9 membrane depolarization during action potential GO:0086010 9.37 CACNA1A CACNA1B
10 membrane depolarization GO:0051899 9.26 CACNA1A CACNA1B
11 response to pain GO:0048265 9.16 CACNA1A CACNA1B
12 calcium ion transport GO:0006816 9.13 CACNA1A CACNA1B CACNB2
13 calcium ion transmembrane transport GO:0070588 8.8 CACNA1A CACNA1B CACNB2

Molecular functions related to Lambert-Eaton Myasthenic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium channel activity GO:0005262 9.33 CACNA1A CACNA1B CACNB2
2 voltage-gated calcium channel activity GO:0005245 9.13 CACNA1A CACNA1B CACNB2
3 high voltage-gated calcium channel activity GO:0008331 8.8 CACNA1A CACNA1B CACNB2

Sources for Lambert-Eaton Myasthenic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....